AnswersPublished14 sources
ByteDance’s Anew Labs Raises $290M at a $1.5B Valuation
Anew Labs raised $290 million in its inaugural external round at a reported $1.5 billion valuation. HSG, IDG Capital, and Hillhouse Investment led the financing; 5Y Capital co led, alongside investors including Gaorong Ventures, Primavera Venture Partners, Boyu Capital, SBP Group, and Shanghai Future Industries Fund.
Published byEdited with GPT-5.6 TerraImages generated with GPT Image 2
Research answer
Key takeaways
- Anew Labs raised $290 million in its inaugural external round at a reported $1.5 billion valuation.
- HSG, IDG Capital, and Hillhouse Investment led the financing; 5Y Capital co led, alongside investors including Gaorong Ventures, Primavera Venture Partners, Boyu Capital, SBP Group, and Shanghai Future Industries Fund.
- The spin off reflects the different operating and management requirements of AI drug discovery versus ByteDance’s core internet businesses.
AI Prompt
openai.comCreate a landscape editorial hero image for this Studio Global article: What did ByteDance’s spin-off Anew Labs, its Shanghai-based AI drug-discovery unit, raise in its inaugural external funding round; what valu. Article summary: Anew Labs raised $290 million in its first outside financing, valuing the Shanghai-headquartered AI drug-discovery company at $1.5 billion. ByteDance will retain a 56% stake. [1] - **Investors:** The round was led by HSG. Topic tags: general, news, general web, user generated. Style: premium digital editorial illustration, source-backed research mood, clean composition, high detail, modern web publication hero. Use reference image context only for broad subject, composition, and topical grounding; do not copy the exact image. Avoid: logos, brand marks, copyrighted characters, real person likenesses, fake screenshots, UI text, readable text, watermarks, charts w
Anew Labs, ByteDance’s Shanghai-headquartered AI drug-discovery spin-off, has completed a $290 million first external financing at a reported $1.5 billion valuation. ByteDance is expected to retain a 56% stake following the round. 1
Funding round at a glance
The financing was led by HSG—formerly Sequoia China—IDG Capital, and Hillhouse Investment. 5Y Capital was a co-lead. Reported participants included Gaorong Ventures, Primavera Venture Partners, Boyu Capital, SBP Group, and the state-backed Shanghai Future Industries Fund. 1
The reported ownership structure is notable: Anew becomes independently financed while ByteDance remains its majority shareholder. That gives the new company access to external capital and biotech-focused investors without severing ByteDance’s control. 1
Why ByteDance spun out the unit
According to people familiar with the transaction, ByteDance separated Anew Labs to support its longer-term development because AI drug discovery follows a different industry logic and management model from the parent company’s core operations. 1
In practical terms, the move creates a dedicated company around a field that combines AI research with drug-development work, rather than treating it as an internal technology unit.
What Anew Labs is building
Anew Labs describes its public technology stack as spanning several stages of computational drug discovery. Its offerings include:
- AnewDDE, an agentic drug-discovery engine integrating structure prediction, molecular design, binding affinity, and scientific reasoning
- AnewFold, for protein and molecular-complex structure prediction
- AnewSampling, a dynamics-aware AI engine
- AnewOmni, an all-atom generative model for biomolecular interactions
- AnewDesign, for antibody design and optimization
- AnewMind, a scientific-reasoning language model
20
The company says AnewDDE is designed to incorporate experimental feedback into a closed-loop discovery process for difficult therapeutic targets. 20
Locations and pipeline
Reporting in May identified Anew Labs as operating from Shanghai, Singapore, and San Jose, California. 23
25 Its drug-development portfolio was reported to include four pipeline candidates at that time.
25
Publicly described work includes a small-molecule program aimed at IL-17, alongside other preclinical programs. As with any preclinical drug-discovery effort, the funding and platform announcements do not establish clinical efficacy or regulatory approval.
Why the deal matters
The round places Anew Labs among the better-funded AI drug-discovery companies emerging from a major consumer-internet group. The key distinction is not simply the $290 million raise: it is the structure of the spin-off, which pairs outside biotech and venture backing with ByteDance’s continuing 56% ownership. 1
For Anew, the next test is execution—turning its AI models and discovery platform into programs that progress through the long, evidence-intensive path of drug development.
Studio Global AI
Continue your research
This page includes a source-backed answer you can continue inside Studio Global.
People also ask
What is the short answer to "ByteDance’s Anew Labs Raises $290M at a $1.5B Valuation"?
Anew Labs raised $290 million in its inaugural external round at a reported $1.5 billion valuation.
What are the key points to validate first?
Anew Labs raised $290 million in its inaugural external round at a reported $1.5 billion valuation. HSG, IDG Capital, and Hillhouse Investment led the financing; 5Y Capital co led, alongside investors including Gaorong Ventures, Primavera Venture Partners, Boyu Capital, SBP Group, and Shanghai Future Industries Fund.
What should I do next in practice?
The spin off reflects the different operating and management requirements of AI drug discovery versus ByteDance’s core internet businesses.